

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/817,334
				Filing Date	April 2, 2004
				First Named Inventor	Hammock, Bruce D.
				Art Unit	1654
				Examiner Name	Kosar, Andrew D.
Sheet	1	of	3	Attorney Docket Number	02307W-131010US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
	C1	US-3,587,060	06-22-1971	Quinn et al.	
	C2	US-3,755,415	08-28-1973	Richter et al.	
	C3	US-5,962,455-A	10-05-1999	Blum et al.	
	C4	US-6,344,358-B1	02-05-2002	Matsuoka et al.	
	C5	US-2002/0090732-A1	07-11-2002	Matsuoka et al.	
	C6	US-6,613,572-B2	09-02-2003	Matsuoka et al.	
	C7	US-2004/0014745-A1	01-22-2004	Yamada et al.	
	C8	US-2004/0054187-A1	03-18-2004	Mammen et al.	
	C9	US-6,710,043-B1	03-23-2004	Yamada et al.	
		US-			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	C10	CA	2 360 360	A1	07-20-2000	Fujisawa Pharmaceutical Co., Ltd.		<input type="checkbox"/>
	C11	EP	0 503 627	A1	09-16-1992	The Green Cross Corporation		<input type="checkbox"/>
	C12	EP	1 031 564	A1	08-30-2000	Klinge Pharma GmbH		<input type="checkbox"/>
	C13	DD	123 466	A	12-19-1976	Willtzer	Translation of Abstract Only	<input checked="" type="checkbox"/>
	C14	JP	4-13666	A	01-17-1992	Yamanouchi Pharma Co., Ltd.	Translation of Abstract Only	<input checked="" type="checkbox"/>
	C15	JP	7-133224	A	05-23-1995	Kyowa Hakko Kogyo KK	Translation of Abstract Only	<input checked="" type="checkbox"/>
	C16	JP	2001-158789	A	06-12-2001	Nikken Chemicals Co., Ltd.	Translation of Abstract Only	<input checked="" type="checkbox"/>
	C17	JP	2003-522120	T	07-22-2003	Fujisawa Pharmaceutical Co., Ltd.	Translation of Abstract Only	<input checked="" type="checkbox"/>
	C18	JP	2004-002414	A	01-08-2004	Fujisawa Pharmaceutical Co.	Translation of Abstract Only	<input checked="" type="checkbox"/>
	C19	RU	2 208 608	C2	07-20-2003	Fudzisava Farms Jutikal Ko Lt	Translation of Abstract Only	<input checked="" type="checkbox"/>
	C20	WO	99/07700	A1	02-18-1999	Smithkline Beecham Plc.		<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/817,334
				Filing Date	April 2, 2004
				First Named Inventor	Hammock, Bruce D.
				Art Unit	1654
				Examiner Name	Kosar, Andrew D.
				Attorney Docket Number	02307W-131010US
Sheet	2	of	3		

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	C21	WO	99/09024	A1	02-25-1999	Smithkline Beecham Plc.		<input type="checkbox"/>
	C22	WO	00/42011	A1	07-20-2000	Fujisawa Pharmaceutical Co., Ltd.		<input type="checkbox"/>
	C23	WO	00/48593	A1	08-24-2000	The Regents of the University of California		<input type="checkbox"/>
	C24	WO	00/72834	A2, A3	12-07-2000	Fujisawa Pharmaceutical Co., Ltd.		<input type="checkbox"/>
	C25	WO	00/76457	A2, A3	12-21-2000	Smithkline Beecham Corporation		<input type="checkbox"/>
	C26	WO	01/42212	A1	06-14-2001	Advanced Medicine, Inc.		<input type="checkbox"/>
	C27	WO	02/14311	A2, A3	02-21-2002	Amgen Inc.		<input type="checkbox"/>
	C28	WO	03/009845	A1	02-06-2003	Schering Corporation		<input type="checkbox"/>
	C29	WO	03/061597	A2, A3	07-31-2003	The Regents of the University of California		<input type="checkbox"/>
	C30	WO	03/070242	A1	08-28-2003	Celtech R&D Limited		<input type="checkbox"/>
	C31	WO	03/070727	A1	08-28-2003	Amgen Inc.		<input type="checkbox"/>
	C32	WO	03/076426	A2, A3	09-18-2003	Pharmacia & Upjohn Company		<input type="checkbox"/>
	C33	WO	03/062861	A2, A3	10-09-2003	Glaxo Group Limited		<input type="checkbox"/>
	C34	WO	03/097618	A1	11-27-2003	Glaxo Group Limited		<input type="checkbox"/>
	C35	WO	03/097586	A1	11-27-2003	Janssen Pharmaceutica N.V.		<input type="checkbox"/>
	C36	WO	2004/007459	A2, A3	01-22-2004	Janssen Pharmaceutica N.V.		<input type="checkbox"/>

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A&B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/817,334
				Filing Date	April 2, 2004
				First Named Inventor	Hammock, Bruce D.
				Art Unit	1654
				Examiner Name	Kosar, Andrew D.
Sheet	3	of	3	Attorney Docket Number	02307W-131010US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C37	AN 2000: 473143, CAPLUS abstract of Jefferson et al., "Solid-phase synthesis of a heterocyclic ethylenediamine-derivatized library," J. Comb. Chem., 2(5):441-444 (2000) <i>abstract only</i>	<input type="checkbox"/>
			<input type="checkbox"/>

Examiner Signature	/Andrew D. Kosar/	Date Considered	09/28/2008
-----------------------	-------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.